%PDF-1.4
%
56 0 obj
<>
endobj
53 0 obj
<>
endobj
172 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-11T10:45:07Z
2024-03-28T23:59:46-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T23:59:46-07:00
application/pdf
Heather
2003-582.dec
uuid:983e92bf-1dd1-11b2-0a00-8008277d8900
uuid:983e92c1-1dd1-11b2-0a00-d30000000000
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
57 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
187 0 obj
[191 0 R]
endobj
188 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0896 Tw 10 0 0 10 53.5 735.3264 Tm
[(genes on the development of this complication in )17.7 (TRAPS,)]TJ
0.1544 Tw 0 -1.2 TD
(as similarly reported for another form of hereditary fever)Tj
0.0836 Tw T*
[(syndrome, FMF)79.7 (. For this disease, 2 studies have identified)]TJ
0.069 Tw T*
[(the serum amyloid )54.8 (A1 )]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.5 (\002)]TJ
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 11.2441 0 Td
(\(SAA1)Tj
/T1_2 1 Tf
0 Tc (\002)Tj
/T1_1 1 Tf
[0.1 (/)]TJ
/T1_2 1 Tf
[0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.06911 Tw [0.1 (\) genotype as such a)]TJ
0.02499 Tw -11.2441 -1.2 Td
(genetic factor predisposing individuals to amyloidosis)Tj
0 Tc 0 Tw 7.5 0 0 7.5 271.0831 690.6265 Tm
[(1)49.2 (1,12)]TJ
10 0 0 10 287.5894 687.3264 Tm
(.)Tj
-0.00011 Tc 0.0457 Tw -22.2089 -1.2 Td
(In accord with previous reports)Tj
0 Tc 0 Tw 7.5 0 0 7.5 192.2709 678.6265 Tm
(13)Tj
-0.00011 Tc 0.0457 Tw 10 0 0 10 199.7709 675.3264 Tm
(, in our case colchicine)Tj
0.12669 Tw -14.6271 -1.2 Td
[(treatment was not ef)17.7 (fective for control of the attacks, and)]TJ
0.0536 Tw T*
(did not prevent recurrence of amyloidosis in the renal allo-)Tj
0.2603 Tw T*
(graft. In addition, the immunosuppressive medication to)Tj
-0.00301 Tw T*
[(prevent transplant rejection had no clear beneficial ef)17.7 (fect on)]TJ
0.007 Tw T*
(the attacks, and could not prevent the deposition of amyloid)Tj
0.02499 Tw T*
(in the graft.)Tj
0.0417 Tw 1.2 -1.2 Td
[(Recently)64.8 (, it has been reported that etanercept might be a)]TJ
0.08009 Tw -1.2 -1.2 Td
[(promising treatment for )17.7 (TRAPS. )17.6 (This drug is a )17.6 (TNFR2:Fc)]TJ
0.1638 Tw T*
[(fusion protein, which restores the pool of soluble )17.7 (TNF-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 23.3691 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.22729 Tw -23.3691 -1.2 Td
(binding proteins and thereby prevents interaction of this)Tj
0.31979 Tw T*
(cytokine with membrane-bound receptors)Tj
0 Tc 0 Tw 7.5 0 0 7.5 229.9697 546.6265 Tm
(13,14)Tj
-0.00011 Tc 0.265 Tw 10 0 0 10 246.8447 543.3264 Tm
[(. After )-54.8 (the)]TJ
0.06709 Tw -19.3345 -1.2 Td
[(diagnosis of )17.8 (TRAPS was confirmed, therapy with subcuta-)]TJ
0.0042 Tw T*
[(neous etanercept was introduced in the son. )54.8 (After that, renal)]TJ
0.0152 Tc 0.3597 Tw T*
(function stabilized and proteinuria decreased to non-)Tj
-0.00011 Tc 0.15089 Tw T*
(nephrotic range. In addition, it led to an increase in food)Tj
0.07021 Tw T*
(intake resulting in a sustained weight gain. So far no addi-)Tj
0.26489 Tw T*
(tional oral prednisolone has been needed to control the)Tj
0.0184 Tw T*
[(inflammatory activity)64.8 (, which has encouraged us to continue)]TJ
-0.0023 Tw T*
(the therapeutic and prophylactic application of etanercept in)Tj
0.02499 Tw T*
(this patient.)Tj
0.1203 Tw 1.2 -1.2 Td
[(W)79.9 (e describe a severe presentation of )17.7 (TRAPS with sys-)]TJ
0.0752 Tw -1.2 -1.2 Td
(temic amyloidosis recurring in a renal graft, despite a sup-)Tj
0.2646 Tw T*
[(posedly benign underlying mutation. Our patient\325)54.8 (s good)]TJ
0.02499 Tw T*
(clinical response to etanercept therapy is encouraging.)Tj
/T1_3 1 Tf
0.00011 Tc 0.0033 Tw 0 -2.4 TD
[(Note added to pr)37 (oof:)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.0034 Tw 8.5317 0 Td
(At the age of 26 years, the sister of the)Tj
0.1228 Tw -8.5317 -1.2 Td
(index patient \(Figure 4; III, 2\) developed marked protein-)Tj
0.17821 Tw 0 -1.2 TD
(uria, and subsequent biopsy of the kidney revealed amy-)Tj
0.02499 Tw T*
[(loidosis, type )54.8 (AA.)]TJ
/T1_4 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 60.5 293.3264 Tm
[(1.)-875.1 (McDermott MF)79.7 (, )54.8 (Aksentijevich I, Galon J, et al. Germline mutations)]TJ
1.675 -1.25 Td
[(in the extracellular domains of the 55 kDa )17.7 (TNF receptor)39.7 (, )17.7 (TNFR1,)]TJ
0 -1.25 TD
(define a family of dominantly inherited autoinflammatory )Tj
T*
(syndromes. Cell 1999;97:133-44.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Hull KM, Drewe E, )54.8 (Aksentijevich I, et al. )17.7 (The )17.7 (TNF )]TJ
1.675 -1.25 Td
[(receptor)19.7 (-associated periodic syndrome \(TRAPS\): emer)17.7 (ging )]TJ
T*
[(concepts of an autoinflammatory disorder)54.8 (. Medicine Baltimore)]TJ
0 Tc 0 Tw T*
(2002;81:349-68.)Tj
-0.00011 Tc 0.02499 Tw 31.325 64.171 Td
[(3.)-875.1 (Aksentijevich I, Galon J, Soares M, et al. )17.7 (The tumor)19.7 (-necrosis-factor)]TJ
1.675 -1.25 Td
[(receptor)19.7 (-associated periodic syndrome: new mutations in)]TJ
T*
(TNFRSF1A, ancestral origins, genotype-phenotype studies, and)Tj
T*
[(evidence for further genetic heterogeneity of periodic fevers. )54.8 (Am )]TJ
T*
(J Hum Genet 2001;69:301-14.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Rocken C, Shakespeare )54.8 (A. Pathology)64.8 (, diagnosis and pathogenesis)]TJ
-0.0298 Tw 1.675 -1.25 Td
[(of AA)-220.2 (amyloidosis. )-37.1 (V)59.8 (irchows Arch )-54.8 (2002;440:1)36.8 (1)36.8 (1-22.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Hamed G, Hef)17.7 (fess CS, Shmookler BM, )17.7 (W)79.9 (enig BM. )54.8 (Amyloid goiter)54.8 (.)]TJ
1.675 -1.25 Td
[(A)-220.1 (clinicopathologic study of 14 cases and review of the literature.)]TJ
T*
(Am J Clin Pathol 1995;104:306-12.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Ozdemir BH, )54.8 (Akman B, Ozdemir FN. )54.8 (Amyloid goiter in familial)]TJ
1.675 -1.25 Td
(Mediterranean fever: a clinicopathologic study of 10 cases. Ren)Tj
T*
(Fail 2001;23:659-67.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Sbai )54.8 (A, )17.7 (W)79.9 (echsler B, Leenhardt L, et al. )54.8 (Amyloid goiter as the initial)]TJ
1.675 -1.25 Td
(manifestation of systemic amyloidosis due to familial)Tj
T*
[(Mediterranean fever with homozygous MEFV)-257.3 (mutation. )17.7 (Thyroid)]TJ
0 Tc 0 Tw T*
[(2001;1)36.9 (1:397-400.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Jadoul M, Dode C, Cosyns JP)110.7 (, et al. )54.8 (Autosomal-dominant periodic)]TJ
1.675 -1.25 Td
[(fever with )54.8 (AA)-220.2 (amyloidosis: Novel mutation in tumor necrosis )]TJ
T*
(factor receptor 1 gene. Kidney Int 2001;59:1677-82.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Rosen-W)79.7 (olf)17.7 (f )54.8 (A, Kreth HW)91.7 (, Hofmann S, et al. Periodic fever)]TJ
1.675 -1.25 Td
[(\(TRAPS\) caused by mutations in the )17.7 (TNF alpha receptor 1)]TJ
T*
(\(TNFRSF1A\) gene of three German patients. Eur J Haematol)Tj
0 Tc 0 Tw T*
(2001;67:105-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Dode C, )54.8 (Andre M, Bienvenu )17.7 (T)74 (, et al. )17.7 (The enlar)17.7 (ging clinical, )]TJ
2.175 -1.25 Td
(genetic, and population spectrum of tumor necrosis factor )Tj
T*
[(receptor)19.7 (-associated periodic syndrome. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:2181-8.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Cazaneuve C, )54.8 (Ajrapetyan H, Papin S, et al. Identification of )]TJ
2.1381 -1.25 Td
[(MEFV)91.7 (-independent modifying genetic factors for familial)]TJ
T*
[(Mediterranean fever)54.8 (. )54.8 (Am J Hum Genet 2000;67:1)36.8 (136-43.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh)]TJ
2.175 -1.25 Td
[(A. )17.7 (The contribution of genotype at the MEFV)-257.3 (and SAA1 loci to)]TJ
T*
(amyloidosis and disease severity in patients with familial)Tj
T*
[(Mediterranean fever)54.8 (. )54.8 (Arthritis Rheum 2003;48:1)36.8 (149-55.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Drewe E, McDermott EM, Powell PT)73.9 (, Isaacs JD, Powell RJ.)]TJ
2.175 -1.25 Td
(Prospective study of anti-tumour necrosis factor receptor )Tj
T*
(superfamily 1B fusion protein, and case study of anti-tumour )Tj
T*
[(necrosis factor receptor superfamily 1A)-220.2 (fusion protein, in tumour)]TJ
T*
(necrosis factor receptor associated periodic syndrome \(TRAPS\):)Tj
T*
(clinical and laboratory findings in a series of seven patients.)Tj
T*
(Rheumatology Oxford 2003;42:235-9.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Drewe E, McDermott EM, Powell RJ. )17.7 (T)35 (reatment of the nephrotic)]TJ
2.175 -1.25 Td
(syndrome with etanercept in patients with the tumor necrosis factor)Tj
T*
[(receptor)19.7 (-associated periodic syndrome. N Engl J Med)]TJ
0 Tc 0 Tw T*
(2000;343:1044-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Cordell JL, Falini B, Erber )17.7 (WN, et al. Immunoenzymatic labeling)]TJ
2.175 -1.25 Td
(of monoclonal antibodies using immune complexes of alkaline)Tj
T*
[(phosphatase and monoclonal anti-alkaline phosphatase \(AP)91.7 (AAP)]TJ
T*
(complexes\). J Histochem Cytochem 1984;32:219-29.)Tj
ET
0 0 0 1 K
53.46 77 m
558.47 77 l
S
0 0 0 0 k
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tc 0 Tw 8 0 0 8 53.3216 57.2343 Tm
(2522)Tj
ET
0 0 0 0 k
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 419.8613 57.2343 Tm
(The Journal of Rheumatology 2004; 31:12)Tj
ET
0 0 0 0 k
/GS0 gs
101.13 82.08 407.5 -10.83 re
f*
0.5 w
101.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>stream
8;Z\7d>e;P#iu#8d,2BE$Nhk.ZM(+BQeU04*JZpN>0;gH$CV1F..k_6(_ONP=ca`D
_Z@oK(Pp/Qk>-*,Y`?^jJaB`4+H`EI^0hk7ilP)TL]G^?,!fHFm)c'2?g@mCYn$50
lGO2aLUme-VE\'ZYKpK(4UO"MVg1"r)%,7Hh
/@6T'I>.nsqTDWT4;gV82/R9hG>'"DUEj-$$4A[]eKs+K,<K[FFMNb:Wp
$jnttjW]B,[We_E&K'[K"H9cVCr`:pBf>2D_ZpHF+mX1M?S!u>V>"!,h8>X>+\i;K!9cT_h
X:fq#P?:VsoF=:@O90`T@W1&3ET9M-o-V\B+\I(VDt2PnlU`_j(O,8+rt0__!6qaEj8~>
endstream
endobj
40 0 obj
[/Indexed/DeviceRGB 255 39 0 R]
endobj
39 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
112 0 obj
<>
endobj
67 0 obj
<>
endobj
71 0 obj
<>
endobj
62 0 obj
<>
endobj
87 0 obj
<>
endobj
103 0 obj
<>
endobj
177 0 obj
<>
endobj
88 0 obj
<>
endobj
95 0 obj
<>stream
HLSkPW%d/4ZXUFyU-A"V*ѢjjHpZVH E1"uh_؎j[:ӳɌp3w{|4B4JJs'-S`6F1PhZex"YhZ~Nu(t==Aii:l|5hc/(,o)'L'cF1),V(4;4[]*KBsTQLZ`ivj1SMbd5盤=OL%f1ihNKE}(ZZLmǧ'huQc)jzP5PU"*"@=!/l It
(eH<,/gi~ݣ+F2ΠO,dm%*X+jNpMMP4=T]R =PVju!EHUbd